Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. News
  7. Summary
    ADXN   CH0029850754


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release: Addex to Participate at the 4 Annual Neuroscience Innovation Forum

04/26/2021 | 01:00am EDT
   Geneva, Switzerland, April 26, 2021 - Addex Therapeutics 
Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical 
company pioneering allosteric modulation-based drug discovery and 
development, announced today that Tim Dyer, Chief Executive Officer, 
will present at the 4 Annual Neuroscience Innovation Forum 
(April 26 - 30, 2021). 
   In his presentation, Mr Dyer will provide a corporate update and discuss 
recent developments at Addex. The video presentation will be available 
for viewing to registered participants at the forum. Mr Dyer will also 
be speaking at the Parkinson's & Movement Disorders Panel scheduled for 
13:20 EDT, April 28, 2021. 
   Management will be available for virtual one-on-one meetings throughout 
the conference. For more information or to schedule a one-on-one meeting 
with management, please contact your conference representative or 
   About Addex Therapeutics: 
   Addex Therapeutics 
is a clinical-stage pharmaceutical company focused on the development 
and commercialization of an emerging class of novel orally available 
small molecule drugs known as allosteric modulators for neurological 
disorders. Allosteric modulators offer several potential advantages over 
conventional non-allosteric molecules and may offer an improved 
therapeutic approach to conventional "orthosteric" small molecule or 
biological drugs. Adder's allosteric modulator drug discovery platform 
targets receptors and other proteins that are recognized as essential 
for therapeutic intervention. adder's lead drug candidate, dipraglurant 
(mGlu5 negative allosteric modulator or NAM), is poised to start a 
pivotal registration clinical trial for Parkinson's disease levodopa 
induced dyskinesia (PD-LID) in Q2 2021. Addex is also investigating 
dipraglurant's therapeutic use in blepharospasm (a type of dystonia), 
for which a clinical trial is expected to be initiated in Q2 2021. 
Addex's third clinical program, ADX71149 (mGlu2 positive allosteric 
modulator or PAM), developed in collaboration with Janssen 
Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept 
clinical study for the treatment of epilepsy in Q2 2021. Addex's GABAB 
PAM program has been licensed to Indivior PLC who are focused on 
development for the treatment of addiction. Preclinical programs include 
GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild 
neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 
PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss 
Exchange and the NASDAQ Capital Market and trades under the ticker 
symbol "ADXN". 
   Press Contacts: 
Tim Dyer                   Mike Sinclair              James Carbonara 
 Chief Executive Officer    Partner, Halsin Partners   Hayden IR 
 +41 22 884 15 55           +44 (0) 20 7318 2955       (646)-755-7412 
 PR@addextherapeutics.com   msinclair@halsin.com       james@haydenir.com 
   Forward Looking Statements: 
   This press release contains forward-looking statements within the 
meaning of the Private Securities Litigation Reform Act of 1995, as 
amended, including in respect of the anticipated initiation and progress 
of clinical trials and preclinical studies, and its future financing 
activities. The words "may," "will," "could," "would," "should," "expect, 
" "plan," "anticipate," "intend," "believe," "estimate," "predict," 
"project," "potential," "continue," "target" and similar expressions are 
intended to identify forward-looking statements, although not all 
forward-looking statements contain these identifying words. Any 
forward-looking statements in this press release, are based on 
management's current expectations and beliefs and are subject to a 
number of risks, uncertainties and important factors that may cause 
actual events or results to differ materially from those expressed or 
implied by any forward-looking statements contained in this press 
release, including, without limitation, uncertainties related to market 
conditions. These and other risks and uncertainties are described in the 
Company's Annual Report on Form 20-F filed with the SEC on March 11, 
2021, as well as market conditions and regulatory review. 
   Any forward-looking statements contained in this press release represent 
Addex Therapeutics' views only as of the date hereof and should not be 
relied upon as representing its views as of any subsequent date. Addex 
Therapeutics explicitly disclaims any obligation to update any 
forward-looking statements, except as required by law. 

(END) Dow Jones Newswires

April 26, 2021 01:00 ET (05:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ADDEX THERAPEUTICS LTD 0.63% 1.6 Delayed Quote.-19.60%
BRITISH POUND / EURO (GBP/EUR) 0.06% 1.16534 Delayed Quote.4.04%
DJ INDUSTRIAL 0.04% 34479.6 Delayed Quote.12.61%
US DOLLAR / EURO (USD/EUR) -0.02% 0.825798 Delayed Quote.0.34%
06/07ADDEX THERAPEUTICS  : Commences Enrollment in Phase 2 Trial of Epilepsy Drug
06/07ADDEX THERAPEUTICS  : First patients enrolled into multi-center U.S. study (Form..
06/07ADDEX THERAPEUTICS  : Enrolls First Patient in Mid-Stage Study of Epilepsy Drug
06/07PRESS RELEASE : Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
06/07Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
05/24PRESS RELEASE : Addex to Participate at the Benchmark Company Healthcare House C..
05/24ADDEX THERAPEUTICS  : to Participate at the Benchmark Company Healthcare House C..
05/24Addex to Participate at the Benchmark Company Healthcare House Call Conferenc..
05/17PRESS RELEASE : Addex's Dipraglurant Restores Synaptic Plasticity in Models of D..
05/17Addex's Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
More news
Sales 2021 1,61 M 1,79 M 1,79 M
Net income 2021 -15,1 M -16,7 M -16,7 M
Net Debt 2021 5,28 M 5,87 M 5,87 M
P/E ratio 2021 -3,72x
Yield 2021 -
Capitalization 69,7 M 77,6 M 77,6 M
EV / Sales 2021 46,6x
EV / Sales 2022 76,6x
Nbr of Employees 27
Free-Float 77,4%
Duration : Period :
Addex Therapeutics Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADDEX THERAPEUTICS LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 1,08 CHF
Last Close Price 1,60 CHF
Spread / Highest target -32,5%
Spread / Average Target -32,5%
Spread / Lowest Target -32,5%
EPS Revisions
Managers and Directors
Timothy Dyer Chief Executive Officer & Director
Lénaic Teyssédou Head-Finance
Vincent M. Lawton Chairman
Roger G. Mills Director & Chief Medical Officer
Raymond George Hill Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416